wird es noch spannend die Tage werden Jungs !!
hoffe am 09.05.2016 kommt was bezüglich Merger, Sale usw. ;-)
Commenting on this strategic option process, Dr. Michael Berendt, Chief Executive Officer and Chief Scientist noted:
"Since we received our Complete Response Letter with the U.S. FDA in February, we have been working closely with our board of directors, to identify strategic options that will deliver value for our shareholders in the event that commercial approval for MCNA in the United States would require another long term clinical study. This strategic option review includes the sale and/or merger of the company, the sale and/or licensing of our assets and the acquisition of commercial and/or pre-commercial healthcare assets that could be developed leveraging our current cash and human resources. This process is ongoing and will accelerate now that we have a definitive ruling from the FDA and may involve the engagement of an investment bank to assist and facilitate this review process.
My management team and our board of directors are acutely aware that one of our key assets is our current cash position of approximately C$44 million. As such, we continue to review and will implement additional cost reduction strategies in the near term and in the future as they are identified. A further report on these efforts will be made in conjunction with the release of our third quarter results expected the week of May 9th."